Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.43 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.43 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.43 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13820080 | 0.86 | PARP1 (0.45) | PARP1CHEK1PIM1RPS6KA3LMNA | |
| SCHEMBL874742 | 0.85 | PARP1 (0.54) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL874689 | 0.78 | PARP1 (0.54) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1841772 | 0.78 | PARP1 (0.54) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3262503 | 0.78 | PIM1 (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL874998 | 0.77 | KDM4E (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9483856 | 0.75 | IP6K1 (0.38) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17150325 | 0.74 | PARP1 (0.46) | PARP1KDM4EMAPT | |
| SCHEMBL19153064 | 0.73 | PARP1 (0.34) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL3757350 | 0.73 | PARP1 (0.59) | PARP1ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114049-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170114049-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170114049-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170022171-A1 | 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022171-A1 | 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| WO-2016116058-A1 | TRIAZINE HETEROCYCLIC COMPOUND WITH NEMATICIDAL ACTIVITY AND PREPARATION METHOD THEREFOR AND USAGE THEREOF | 华东理工大学 | 2016-07-28 | — | — | WO | disclosed |
| WO-2015150350-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATOY TRACT DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150363-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150366-A1 | CYCLICALLY SUBSTITUTED PHENOL ETHER DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2074093-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008023336-A2 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-28 | — | — | WO | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-5234925-A | Anticarcinogenic agent | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993004051-A1 | 2-AZA-2-DESAMINO ANALOGUES OF 5,8-DIDEAZAFOLIC ACID | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114049-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | CA5A, PC, CA5B | PARP1 2898/4885TUBB4A 1777/4885TUBB 1367/4885 |
| US-20170022171-A1 | 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACIDS AND THEIR USE | PC, PYCR1, PCCA | PARP1 1624/4885TUBB4A 2621/4885TUBB 2395/4885 |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP12 | PARP1 1162/4885TUBB4A 2906/4885TUBB 2454/4885 |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | PARP1 400/4885TUBB4A 1065/4885TUBB 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.